These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22674340)

  • 1. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
    Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
    Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
    Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
    J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
    Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
    J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
    Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
    Front Immunol; 2018; 9():2841. PubMed ID: 30619250
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
    Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
    J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
    Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
    Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
    Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China.
    Wang S; Nie J; Wang Y
    Virus Res; 2011 Jan; 155(1):137-46. PubMed ID: 20875470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.
    Andrabi R; Makhdoomi MA; Kumar R; Bala M; Parray H; Gupta A; Kotnala A; Thirumurthy V; Luthra K
    J Clin Immunol; 2014 May; 34(4):504-13. PubMed ID: 24682667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.
    Andrabi R; Bala M; Kumar R; Wig N; Hazarika A; Luthra K
    PLoS One; 2012; 7(8):e43704. PubMed ID: 22952740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral therapy. [corrected].
    Choudhary AK; Andrabi R; Prakash SS; Kumar R; Choudhury SD; Wig N; Biswas A; Hazarika A; Luthra K
    J Microbiol; 2012 Feb; 50(1):149-54. PubMed ID: 22367950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
    Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
    J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
    Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
    Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.
    Cheedarla N; Precilla KL; Babu H; Vijayan KKV; Ashokkumar M; Chandrasekaran P; Kailasam N; Sundaramurthi JC; Swaminathan S; Buddolla V; Vaniambadi SK; Ramanathan VD; Hanna LE
    Sci Rep; 2017 Apr; 7():46557. PubMed ID: 28436427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.
    Ferreira CB; Merino-Mansilla A; Llano A; Pérez I; Crespo I; Llinas L; Garcia F; Gatell JM; Yuste E; Sanchez-Merino V
    J Virol; 2013 Nov; 87(22):12227-36. PubMed ID: 24006439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.